Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | NR0B2 | Q15466 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330441 | 0.93 | RXRA (0.33) | RXRAPTPN11NR0B2PTGS2 | |
| SCHEMBL13330446 | 0.86 | CNR2 (0.32) | RXRAEPHX2 | |
| SCHEMBL13330411 | 0.85 | CNR2 (0.40) | RXRAPTPN11NR0B2PTGS2EPHX2 | |
| SCHEMBL13330436 | 0.81 | GRIN2D (0.32) | EPHX2 | |
| SCHEMBL13330432 | 0.81 | RXRA (0.36) | RXRAEPHX2 | |
| SCHEMBL13330435 | 0.79 | RARA (0.35) | RXRAEPHX2 | |
| SCHEMBL13330403 | 0.79 | CNR2 (0.38) | RXRAPTPN11NR0B2EPHX2 | |
| SCHEMBL13330427 | 0.75 | RXRA (0.36) | RXRAEPHX2 | |
| SCHEMBL3316211 | 0.74 | TSHR (0.30) | PTPN11NR0B2 | |
| SCHEMBL13330414 | 0.70 | CNR2 (0.44) | RXRAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113816-A1 | METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES | JSC GRINDEKS (LV) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113816-A1 | METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES | AGL, MACROD1, MACROD2 | RXRA 4589/4885PTPN11 4582/4885NR0B2 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.